India's #1 CRO in pharma analytical & food testing, plus preclinical, environment & electronics testing labs.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 9 | 9 |
| Reserves | 190 | 229 | 276 | 310 | 338 | 374 | 407 | 448 |
| Borrowings | 30 | 19 | 15 | 19 | 12 | 9 | 7 | 3 |
| Other Liabilities | 49 | 54 | 65 | 61 | 86 | 79 | 95 | 102 |
| Total Liabilities | 273 | 306 | 360 | 394 | 440 | 467 | 518 | 562 |
| AssetsFixed Assets | 128 | 162 | 168 | 166 | 183 | 230 | 240 | 305 |
| CWIP | 17 | 0 | 12 | 59 | 75 | 38 | 55 | 18 |
| Investments | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 122 | 138 | 174 | 170 | 183 | 198 | 224 | 237 |
| Total Assets | 273 | 306 | 360 | 394 | 440 | 467 | 518 | 562 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 39 | 24 | 37 | 59 | 87 | 61 | 94 | 147 |
| Cash from Investing | -16 | -20 | -32 | -38 | -57 | -76 | -76 | -130 |
| Cash from Financing | -23 | -1 | -5 | -16 | -11 | -2 | -16 | -10 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 23 | 10 | 5 | 20 | 37 | -14 | 17 | 47 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (43.8×) and current (33.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 18.4% growth and a 33× exit, ₹571 only delivers your return if you pay ₹590. The price is currently baking in 18% growth.
EPS grows 18.4%/yr for 5 years, then fades to 6% over 2, exits at 33×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 18.4% | 20.34 |
| FY28 | 18.4% | 24.08 |
| FY29 | 18.4% | 28.52 |
| FY30 | 18.4% | 33.76 |
| FY31 | 18.4% | 39.97 |
| FY32 | 12.2% ·fade | 44.85 |
| FY33 | 6.0% ·fade | 47.54 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.